Volume 11 Supplement 3

Controversies in Breast Cancer 2009

Short communications

Controversies in Breast Cancer 2009.

Edinburgh, UK7-8 September 2009

Controversies in Breast Cancer 2009

Authors: William R Miller

Citation: Breast Cancer Research 2009 11(Suppl 3):S1

Content type: Introduction Published on: 18 December 2009
- View Full Text
- View PDF
Risk factors. Introduction to Session 1

Authors: Anthony Howell and Jack Cuzick

Citation: Breast Cancer Research 2009 11(Suppl 3):S2

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Alcohol consumption and breast cancer risk

Authors: Peter Boyle and Paolo Boffetta

Citation: Breast Cancer Research 2009 11(Suppl 3):S3

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Mammographic density

Authors: Norman F Boyd, Lisa J Martin, Martin Yaffe and Salomon Minkin

Citation: Breast Cancer Research 2009 11(Suppl 3):S4

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Underarm antiperspirants/deodorants and breast cancer

Authors: Philippa D Darbre

Citation: Breast Cancer Research 2009 11(Suppl 3):S5

Content type: Short communication Published on: 13 December 2009
- View Full Text
- View PDF
Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2

Authors: Ian E Smith

Citation: Breast Cancer Research 2009 11(Suppl 3):S6

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Tailored targeted therapy for all: a realistic and worthwhile objective?

Authors: Per Eystein Lønning

Citation: Breast Cancer Research 2009 11(Suppl 3):S7

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Tailored targeted therapy for all: a realistic and worthwhile objective against

Authors: Kathleen I Pritchard

Citation: Breast Cancer Research 2009 11(Suppl 3):S8

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
The potential of new technologies/approaches. Introduction to Sessions 3 and 4

Authors: Mitch Dowsett

Citation: Breast Cancer Research 2009 11(Suppl 3):S9

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients

Authors: Sabine Riethdorf and Klaus Pantel

Citation: Breast Cancer Research 2009 11(Suppl 3):S10

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Gene expression profiling of breast cancer

Authors: Lajos Pusztai

Citation: Breast Cancer Research 2009 11(Suppl 3):S11

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Next-generation sequencing

Next-generation sequencing (also known as massively parallel sequencing) technologies are revolutionising our ability to characterise cancers at the genomic, transcriptomic and epigenetic levels. Cataloguing a...

Authors: Jorge S Reis-Filho

Citation: Breast Cancer Research 2009 11(Suppl 3):S12

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5

Authors: Alan Rodger

Citation: Breast Cancer Research 2009 11(Suppl 3):S13

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Radiation impact in breast cancer

Authors: Joseph Ragaz

Citation: Breast Cancer Research 2009 11(Suppl 3):S14

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Who would have thought a single Ki67 measurement would predict long-term outcome?

Authors: Mitch Dowsett, Roger A'Hern, Janine Salter, Lila Zabaglo and Ian E Smith

Citation: Breast Cancer Research 2009 11(Suppl 3):S15

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Breast tumour stroma is a prognostic indicator and target for therapy

Authors: Anthony Howell, Goran Landberg and Jonas Bergh

Citation: Breast Cancer Research 2009 11(Suppl 3):S16

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6

Authors: Gordon C Wishart and Udi Chetty

Citation: Breast Cancer Research 2009 11(Suppl 3):S17

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

Authors: Ian E Smith

Citation: Breast Cancer Research 2009 11(Suppl 3):S18

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Breast screening has increased the number of mastectomies

Authors: J Michael Dixon

Citation: Breast Cancer Research 2009 11(Suppl 3):S19

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

Authors: Stephen RD Johnston

Citation: Breast Cancer Research 2009 11(Suppl 3):S20

Content type: Section introduction Published on: 18 December 2009
- View Full Text
- View PDF
Are current drug development programmes realising the full potential of new agents? The scenario

Authors: Stephen RD Johnston

Citation: Breast Cancer Research 2009 11(Suppl 3):S21

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
The role of preclinical animal models in breast cancer drug development

Authors: Robert Clarke

Citation: Breast Cancer Research 2009 11(Suppl 3):S22

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Foundation clinical trials

Authors: David Cameron

Citation: Breast Cancer Research 2009 11(Suppl 3):S23

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Authors: Eleanor Gutteridge and John FR Robertson

Citation: Breast Cancer Research 2009 11(Suppl 3):S24

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF
Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy

Authors: Serena Di Cosimo

Citation: Breast Cancer Research 2009 11(Suppl 3):S25

Content type: Short communication Published on: 18 December 2009
- View Full Text
- View PDF

Controversies in Breast Cancer 2009

Short communications

Controversies in Breast Cancer 2009

Risk factors. Introduction to Session 1

Alcohol consumption and breast cancer risk

Mammographic density

Underarm antiperspirants/deodorants and breast cancer

Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2

Tailored targeted therapy for all: a realistic and worthwhile objective?

Tailored targeted therapy for all: a realistic and worthwhile objective against

The potential of new technologies/approaches. Introduction to Sessions 3 and 4

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients

Gene expression profiling of breast cancer

Next-generation sequencing

Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5

Radiation impact in breast cancer

Who would have thought a single Ki67 measurement would predict long-term outcome?

Breast tumour stroma is a prognostic indicator and target for therapy

Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

Breast screening has increased the number of mastectomies

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

Are current drug development programmes realising the full potential of new agents? The scenario

The role of preclinical animal models in breast cancer drug development

Foundation clinical trials

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy

Follow

Annual Journal Metrics

Breast Cancer Research

Contact us